The Apothecaries

Pharmacy has a long history, with remedies ranging from opium to peppermint used across the world for thousands of years. In medieval London, pharmacy was not a distinct trade, but controlled by the Company of Grocers, a guild that regulated the selling of spices, meat, food and drink. As the city developed, so too did the manufacture and dispensing of medicines. The apothecaries, who manufactured and sold drugs, grew keen to break away from their guild, so they could take responsibility for the drugs they produced and ensure these were not adulterated. The apothecaries split from the Company of Grocers in 1617 and became chartered in London as the Worshipful Society of Apothecaries. As well as being responsible for regulating the sale and manufacture of medicines, the new society now had powers to inspect medicines, and you could only be called an apothecary after a seven-year apprenticeship. In 1704 the Worshipful Society of Apothecaries won the Rose Case against the Royal College of Physicians, allowing apothecaries to prescribe medicines as well as dispense them, making them closer to modern general practitioners than pharmacists as we know them today.

The rise of the Chemists and Druggists

A new pharmacy trade emerged in the eighteenth century, as the industrial revolution began. The Worshipful Society of Apothecaries had left a gap in the market by moving into the role of general practitioner, and new chemists and druggists began to spring up in urban areas. They would typically own premises on the high street, where they mixed and dispensed chemicals and medicines, as well as selling tobacco, alcohol, cosmetics and food. Unlike the apothecaries, the chemists and druggists were entirely unregulated, and without a national body to represent them, there was little sense of a pharmacy profession. It was a competitive market, and chemists and druggists focused on the demands of their customers. Many specialised in different products, from chemicals for photography to developing matches - the famous Worcestershire Sauce of John Lea (1791-1882) and William Perrin (1793-1867) become so popular they gave up pharmacy to focus on its production. In 1815, the introduction of the Apothecaries Act would have required all practicing apothecaries to hold a licence, so that the Worshipful Society of Apothecaries could control the chemists and druggists. The Bill required them to either become an apothecary or cease trading in medicines, but the chemists and druggists campaigned against the Bill and won. However, this campaign had made it clear that the new chemists and druggists needed to protect their interests by joining together.

https://www.rpharms.com/about-us/museum/online-exhibitions/the-

history-of-the-royal-pharmaceutical-society/in-the-beginning

The Apothecaries

Pharmacy has a long history, with remedies ranging from opium to peppermint used across the world for thousands of years. In medieval London, pharmacy was not a distinct trade, but controlled by the Company of Grocers, a guild that regulated the selling of spices, meat, food and drink. As the city developed, so too did the manufacture and dispensing of medicines. The apothecaries, who manufactured and sold drugs, grew keen to break away from their guild, so they could take responsibility for the drugs they produced and ensure these were not adulterated. The apothecaries split from the Company of Grocers in 1617 and became chartered in London as the Worshipful Society of Apothecaries. As well as being responsible for regulating the sale and manufacture of medicines, the new society now had powers to inspect medicines, and you could only be called an apothecary after a seven-year apprenticeship. In 1704 the Worshipful Society of Apothecaries won the Rose Case against the Royal College of Physicians, allowing apothecaries to prescribe medicines as well as dispense them, making them closer to modern general practitioners than pharmacists as we know them today.

The rise of the Chemists and Druggists

A new pharmacy trade emerged in the eighteenth century, as the industrial revolution began. The Worshipful Society of Apothecaries had left a gap in the market by moving into the role of general practitioner, and new chemists and druggists began to spring up in urban areas. They would typically own premises on the high street, where they mixed and dispensed chemicals and medicines, as well as selling tobacco, alcohol, cosmetics and food. Unlike the apothecaries, the chemists and druggists were entirely unregulated, and without a national body to represent them, there was little sense of a pharmacy profession. It was a competitive market, and chemists and druggists focused on the demands of their customers. Many specialised in different products, from chemicals for photography to developing matches - the famous Worcestershire Sauce of John Lea (1791-1882) and William Perrin (1793-1867) become so popular they gave up pharmacy to focus on its production. In 1815, the introduction of the Apothecaries Act would have required all practicing apothecaries to hold a licence, so that the Worshipful Society of Apothecaries could control the chemists and druggists. The Bill required them to either become an apothecary or cease trading in medicines, but the chemists and druggists campaigned against the Bill and won. However, this campaign had made it clear that the new chemists and druggists needed to protect their interests by joining together.

https://www.rpharms.com/about-us/museum/online-exhibitions/the-

history-of-the-royal-pharmaceutical-society/in-the-beginning

The Apothecaries

Pharmacy has a long history, with remedies ranging from opium to peppermint used across the world for thousands of years. In medieval London, pharmacy was not a distinct trade, but controlled by the Company of Grocers, a guild that regulated the selling of spices, meat, food and drink. As the city developed, so too did the manufacture and dispensing of medicines. The apothecaries, who manufactured and sold drugs, grew keen to break away from their guild, so they could take responsibility for the drugs they produced and ensure these were not adulterated. The apothecaries split from the Company of Grocers in 1617 and became chartered in London as the Worshipful Society of Apothecaries. As well as being responsible for regulating the sale and manufacture of medicines, the new society now had powers to inspect medicines, and you could only be called an apothecary after a seven-year apprenticeship. In 1704 the Worshipful Society of Apothecaries won the Rose Case against the Royal College of Physicians, allowing apothecaries to prescribe medicines as well as dispense them, making them closer to modern general practitioners than pharmacists as we know them today.

The rise of the Chemists and Druggists

A new pharmacy trade emerged in the eighteenth century, as the industrial revolution began. The Worshipful Society of Apothecaries had left a gap in the market by moving into the role of general practitioner, and new chemists and druggists began to spring up in urban areas. They would typically own premises on the high street, where they mixed and dispensed chemicals and medicines, as well as selling tobacco, alcohol, cosmetics and food. Unlike the apothecaries, the chemists and druggists were entirely unregulated, and without a national body to represent them, there was little sense of a pharmacy profession. It was a competitive market, and chemists and druggists focused on the demands of their customers. Many specialised in different products, from chemicals for photography to developing matches - the famous Worcestershire Sauce of John Lea (1791-1882) and William Perrin (1793-1867) become so popular they gave up pharmacy to focus on its production. In 1815, the introduction of the Apothecaries Act would have required all practicing apothecaries to hold a licence, so that the Worshipful Society of Apothecaries could control the chemists and druggists. The Bill required them to either become an apothecary or cease trading in medicines, but the chemists and druggists campaigned against the Bill and won. However, this campaign had made it clear that the new chemists and druggists needed to protect their interests by joining together.

https://www.rpharms.com/about-us/museum/online-exhibitions/the-

history-of-the-royal-pharmaceutical-society/in-the-beginning

CANCER KILLER Common over-the-counter 3p painkiller 'prevents killer cancers from spreading'

The 3p painkiller was already thought to lower cancer risks but scientists did not know how. Now a "eureka moment" in a mouse experiment has revealed aspirin reduces levels of a chemical that blocks the action of white blood cells. This could help a patient's own immune system to tackle tumours.

Pharmaceutical companies are investing billions of pounds trying to achieve the same thing with super-expensive new drugs. But experts warn Brits should not try to treat themselves with aspirin because there is a risk of side effects. Study author Professor Rahul Roychoudhuri, from Cambridge University, said: "When cancer first spreads there's a unique window of opportunity when cells are particularly vulnerable to immune attack. "We hope that therapies that target this window of vulnerability will have tremendous scope for preventing cancer recurrence."

Co-author Dr Jie Yang added: "It was a eureka moment when we found this effect. "Aspirin has the potential to be less expensive and more accessible than antibody therapies." Aspirin is a painkiller that some people also take long-term as blood thinner to reduce the risk of a stroke or heart attack. It is very cheap and available to buy in shops without a prescription.

Dr Yang found a molecule called TXA2 can suppress cancer-killing T cells, a type of white blood cell. Aspirin lowers TXA2 as part of the way it prevents the blood clotting. Mice with skin cancer that were given aspirin were then found to have a much lower risk of the cancer spreading to other parts of the body.

Writing in the journal Nature, the researchers said this could be because the body's own white blood cells were able to kill loose tumour cells circulating in the blood. Around nine in 10 cancer deaths in humans are in patients whose disease has spread.

Cancer patients 'should not start taking aspirin'

Scientists' reaction to the study was mixed and they warned it is not a miracle cure. Professor Ruth Langley, from University College London, is leading a trial of aspirin on human cancer patients. She said: "This is an important discovery but in a small proportion of people, aspirin can cause serious side-effects, including bleeding or stomach ulcers. "It is important to understand which people with cancer are likely to benefit and always talk to your doctor before starting aspirin."

Dr Harvey Roweth, a cancer biologist at the University of Reading, added: "I don't think we can say that cancer patients should be taking aspirin. "There is some promise that it will help patients in the future but it will need to be considered alongside existing therapies. "Aspirin is

extremely unlikely to become a stand-alone treatment for cancers."

https://www.thesun.co.uk/health/33699118/aspirin-cheap-painkiller-

lower-risk-cancer-spread-cambridge-study/

CANCER KILLER Common over-the-counter 3p painkiller 'prevents killer cancers from spreading'

The 3p painkiller was already thought to lower cancer risks but scientists did not know how. Now a "eureka moment" in a mouse experiment has revealed aspirin reduces levels of a chemical that blocks the action of white blood cells. This could help a patient's own immune system to tackle tumours.

Pharmaceutical companies are investing billions of pounds trying to achieve the same thing with super-expensive new drugs. But experts warn Brits should not try to treat themselves with aspirin because there is a risk of side effects. Study author Professor Rahul Roychoudhuri, from Cambridge University, said: "When cancer first spreads there's a unique window of opportunity when cells are particularly vulnerable to immune attack. "We hope that therapies that target this window of vulnerability will have tremendous scope for preventing cancer recurrence."

Co-author Dr Jie Yang added: "It was a eureka moment when we found this effect. "Aspirin has the potential to be less expensive and more accessible than antibody therapies." Aspirin is a painkiller that some people also take long-term as blood thinner to reduce the risk of a stroke or heart attack. It is very cheap and available to buy in shops without a prescription.

Dr Yang found a molecule called TXA2 can suppress cancer-killing T cells, a type of white blood cell. Aspirin lowers TXA2 as part of the way it prevents the blood clotting. Mice with skin cancer that were given aspirin were then found to have a much lower risk of the cancer spreading to other parts of the body.

Writing in the journal Nature, the researchers said this could be because the body's own white blood cells were able to kill loose tumour cells circulating in the blood. Around nine in 10 cancer deaths in humans are in patients whose disease has spread.

Cancer patients 'should not start taking aspirin'

Scientists' reaction to the study was mixed and they warned it is not a miracle cure. Professor Ruth Langley, from University College London, is leading a trial of aspirin on human cancer patients. She said: "This is an important discovery but in a small proportion of people, aspirin can cause serious side-effects, including bleeding or stomach ulcers. "It is important to understand which people with cancer are likely to benefit and always talk to your doctor before starting aspirin."

Dr Harvey Roweth, a cancer biologist at the University of Reading, added: "I don't think we can say that cancer patients should be taking aspirin. "There is some promise that it will help patients in the future but it will need to be considered alongside existing therapies. "Aspirin is

extremely unlikely to become a stand-alone treatment for cancers."

https://www.thesun.co.uk/health/33699118/aspirin-cheap-painkiller-

lower-risk-cancer-spread-cambridge-study/

CANCER KILLER Common over-the-counter 3p painkiller 'prevents killer cancers from spreading'

The 3p painkiller was already thought to lower cancer risks but scientists did not know how. Now a "eureka moment" in a mouse experiment has revealed aspirin reduces levels of a chemical that blocks the action of white blood cells. This could help a patient's own immune system to tackle tumours.

Pharmaceutical companies are investing billions of pounds trying to achieve the same thing with super-expensive new drugs. But experts warn Brits should not try to treat themselves with aspirin because there is a risk of side effects. Study author Professor Rahul Roychoudhuri, from Cambridge University, said: "When cancer first spreads there's a unique window of opportunity when cells are particularly vulnerable to immune attack. "We hope that therapies that target this window of vulnerability will have tremendous scope for preventing cancer recurrence."

Co-author Dr Jie Yang added: "It was a eureka moment when we found this effect. "Aspirin has the potential to be less expensive and more accessible than antibody therapies." Aspirin is a painkiller that some people also take long-term as blood thinner to reduce the risk of a stroke or heart attack. It is very cheap and available to buy in shops without a prescription.

Dr Yang found a molecule called TXA2 can suppress cancer-killing T cells, a type of white blood cell. Aspirin lowers TXA2 as part of the way it prevents the blood clotting. Mice with skin cancer that were given aspirin were then found to have a much lower risk of the cancer spreading to other parts of the body.

Writing in the journal Nature, the researchers said this could be because the body's own white blood cells were able to kill loose tumour cells circulating in the blood. Around nine in 10 cancer deaths in humans are in patients whose disease has spread.

Cancer patients 'should not start taking aspirin'

Scientists' reaction to the study was mixed and they warned it is not a miracle cure. Professor Ruth Langley, from University College London, is leading a trial of aspirin on human cancer patients. She said: "This is an important discovery but in a small proportion of people, aspirin can cause serious side-effects, including bleeding or stomach ulcers. "It is important to understand which people with cancer are likely to benefit and always talk to your doctor before starting aspirin."

Dr Harvey Roweth, a cancer biologist at the University of Reading, added: "I don't think we can say that cancer patients should be taking aspirin. "There is some promise that it will help patients in the future but it will need to be considered alongside existing therapies. "Aspirin is

extremely unlikely to become a stand-alone treatment for cancers."

https://www.thesun.co.uk/health/33699118/aspirin-cheap-painkiller-

lower-risk-cancer-spread-cambridge-study/

CANCER KILLER Common over-the-counter 3p painkiller 'prevents killer cancers from spreading'

The 3p painkiller was already thought to lower cancer risks but scientists did not know how. Now a "eureka moment" in a mouse experiment has revealed aspirin reduces levels of a chemical that blocks the action of white blood cells. This could help a patient's own immune system to tackle tumours.

Pharmaceutical companies are investing billions of pounds trying to achieve the same thing with super-expensive new drugs. But experts warn Brits should not try to treat themselves with aspirin because there is a risk of side effects. Study author Professor Rahul Roychoudhuri, from Cambridge University, said: "When cancer first spreads there's a unique window of opportunity when cells are particularly vulnerable to immune attack. "We hope that therapies that target this window of vulnerability will have tremendous scope for preventing cancer recurrence."

Co-author Dr Jie Yang added: "It was a eureka moment when we found this effect. "Aspirin has the potential to be less expensive and more accessible than antibody therapies." Aspirin is a painkiller that some people also take long-term as blood thinner to reduce the risk of a stroke or heart attack. It is very cheap and available to buy in shops without a prescription.

Dr Yang found a molecule called TXA2 can suppress cancer-killing T cells, a type of white blood cell. Aspirin lowers TXA2 as part of the way it prevents the blood clotting. Mice with skin cancer that were given aspirin were then found to have a much lower risk of the cancer spreading to other parts of the body.

Writing in the journal Nature, the researchers said this could be because the body's own white blood cells were able to kill loose tumour cells circulating in the blood. Around nine in 10 cancer deaths in humans are in patients whose disease has spread.

Cancer patients 'should not start taking aspirin'

Scientists' reaction to the study was mixed and they warned it is not a miracle cure. Professor Ruth Langley, from University College London, is leading a trial of aspirin on human cancer patients. She said: "This is an important discovery but in a small proportion of people, aspirin can cause serious side-effects, including bleeding or stomach ulcers. "It is important to understand which people with cancer are likely to benefit and always talk to your doctor before starting aspirin."

Dr Harvey Roweth, a cancer biologist at the University of Reading, added: "I don't think we can say that cancer patients should be taking aspirin. "There is some promise that it will help patients in the future but it will need to be considered alongside existing therapies. "Aspirin is

extremely unlikely to become a stand-alone treatment for cancers."

https://www.thesun.co.uk/health/33699118/aspirin-cheap-painkiller-

lower-risk-cancer-spread-cambridge-study/

CANCER KILLER Common over-the-counter 3p painkiller 'prevents killer cancers from spreading'

The 3p painkiller was already thought to lower cancer risks but scientists did not know how. Now a "eureka moment" in a mouse experiment has revealed aspirin reduces levels of a chemical that blocks the action of white blood cells. This could help a patient's own immune system to tackle tumours.

Pharmaceutical companies are investing billions of pounds trying to achieve the same thing with super-expensive new drugs. But experts warn Brits should not try to treat themselves with aspirin because there is a risk of side effects. Study author Professor Rahul Roychoudhuri, from Cambridge University, said: "When cancer first spreads there's a unique window of opportunity when cells are particularly vulnerable to immune attack. "We hope that therapies that target this window of vulnerability will have tremendous scope for preventing cancer recurrence."

Co-author Dr Jie Yang added: "It was a eureka moment when we found this effect. "Aspirin has the potential to be less expensive and more accessible than antibody therapies." Aspirin is a painkiller that some people also take long-term as blood thinner to reduce the risk of a stroke or heart attack. It is very cheap and available to buy in shops without a prescription.

Dr Yang found a molecule called TXA2 can suppress cancer-killing T cells, a type of white blood cell. Aspirin lowers TXA2 as part of the way it prevents the blood clotting. Mice with skin cancer that were given aspirin were then found to have a much lower risk of the cancer spreading to other parts of the body.

Writing in the journal Nature, the researchers said this could be because the body's own white blood cells were able to kill loose tumour cells circulating in the blood. Around nine in 10 cancer deaths in humans are in patients whose disease has spread.

Cancer patients 'should not start taking aspirin'

Scientists' reaction to the study was mixed and they warned it is not a miracle cure. Professor Ruth Langley, from University College London, is leading a trial of aspirin on human cancer patients. She said: "This is an important discovery but in a small proportion of people, aspirin can cause serious side-effects, including bleeding or stomach ulcers. "It is important to understand which people with cancer are likely to benefit and always talk to your doctor before starting aspirin."

Dr Harvey Roweth, a cancer biologist at the University of Reading, added: "I don't think we can say that cancer patients should be taking aspirin. "There is some promise that it will help patients in the future but it will need to be considered alongside existing therapies. "Aspirin is

extremely unlikely to become a stand-alone treatment for cancers."

https://www.thesun.co.uk/health/33699118/aspirin-cheap-painkiller-

lower-risk-cancer-spread-cambridge-study/

CANCER KILLER Common over-the-counter 3p painkiller 'prevents killer cancers from spreading'

The 3p painkiller was already thought to lower cancer risks but scientists did not know how. Now a "eureka moment" in a mouse experiment has revealed aspirin reduces levels of a chemical that blocks the action of white blood cells. This could help a patient's own immune system to tackle tumours.

Pharmaceutical companies are investing billions of pounds trying to achieve the same thing with super-expensive new drugs. But experts warn Brits should not try to treat themselves with aspirin because there is a risk of side effects. Study author Professor Rahul Roychoudhuri, from Cambridge University, said: "When cancer first spreads there's a unique window of opportunity when cells are particularly vulnerable to immune attack. "We hope that therapies that target this window of vulnerability will have tremendous scope for preventing cancer recurrence."

Co-author Dr Jie Yang added: "It was a eureka moment when we found this effect. "Aspirin has the potential to be less expensive and more accessible than antibody therapies." Aspirin is a painkiller that some people also take long-term as blood thinner to reduce the risk of a stroke or heart attack. It is very cheap and available to buy in shops without a prescription.

Dr Yang found a molecule called TXA2 can suppress cancer-killing T cells, a type of white blood cell. Aspirin lowers TXA2 as part of the way it prevents the blood clotting. Mice with skin cancer that were given aspirin were then found to have a much lower risk of the cancer spreading to other parts of the body.

Writing in the journal Nature, the researchers said this could be because the body's own white blood cells were able to kill loose tumour cells circulating in the blood. Around nine in 10 cancer deaths in humans are in patients whose disease has spread.

Cancer patients 'should not start taking aspirin'

Scientists' reaction to the study was mixed and they warned it is not a miracle cure. Professor Ruth Langley, from University College London, is leading a trial of aspirin on human cancer patients. She said: "This is an important discovery but in a small proportion of people, aspirin can cause serious side-effects, including bleeding or stomach ulcers. "It is important to understand which people with cancer are likely to benefit and always talk to your doctor before starting aspirin."

Dr Harvey Roweth, a cancer biologist at the University of Reading, added: "I don't think we can say that cancer patients should be taking aspirin. "There is some promise that it will help patients in the future but it will need to be considered alongside existing therapies. "Aspirin is

extremely unlikely to become a stand-alone treatment for cancers."

https://www.thesun.co.uk/health/33699118/aspirin-cheap-painkiller-

lower-risk-cancer-spread-cambridge-study/